scholarly journals Neurologic outcome of postanoxic refractory status epilepticus after aggressive treatment

Neurology ◽  
2018 ◽  
Vol 91 (23) ◽  
pp. e2153-e2162 ◽  
Author(s):  
Simone Beretta ◽  
Anna Coppo ◽  
Elisa Bianchi ◽  
Clara Zanchi ◽  
Davide Carone ◽  
...  

ObjectiveTo investigate neurologic outcome of patients with cardiac arrest with refractory status epilepticus (RSE) treated with a standardized aggressive protocol with antiepileptic drugs and anesthetics compared to patients with other EEG patterns.MethodsIn the prospective cohort study, 166 consecutive patients with cardiac arrest in coma were stratified according to 4 independent EEG patterns (benign, RSE, generalized periodic discharges [GPDs], malignant nonepileptiform) and multimodal prognostic indicators. Primary outcomes were survival and cerebral performance category (CPC) at 6 months.ResultsRSE occurred in 36 patients (21.7%) and was treated with an aggressive standardized protocol as long as multimodal prognostic indicators were not unfavorable. RSE started after 3 ± 2.3 days after cardiac arrest and lasted 4.7 ± 4.3 days. A benign EEG pattern was recorded in 76 patients (45.8%); a periodic pattern (GPDs) was seen in 13 patients (7.8%); and a malignant nonepileptiform EEG pattern was recorded in 41 patients (24.7%). The 4 EEG patterns were highly associated with different prognostic indicators (low-flow time, clinical motor seizures, N20 responses, neuron-specific enolase, neuroimaging). Survival and good neurologic outcome (CPC 1 or 2) at 6 months were 72.4% and 71.1% for benign EEG pattern, 54.3% and 44.4% for RSE, 15.4% and 0% for GPDs, and 2.4% and 0% for malignant nonepileptiform EEG pattern, respectively.ConclusionsAggressive and prolonged treatment of RSE may be justified in patients with cardiac arrest with favorable multimodal prognostic indicators.

2019 ◽  
Vol 50 (03) ◽  
pp. 197-201
Author(s):  
S. Schmid ◽  
M. Wagner ◽  
C. Goetz ◽  
C. Makowski ◽  
P. Freisinger ◽  
...  

AbstractMitochondrial dynamics such as fission and fusion play a vital role in normal brain development and neuronal activity. DNM1L encodes a dynamin-related protein 1 (Drp1), which is a GTPase essential for proper mitochondrial fission. The clinical phenotype of DNM1L mutations depends on the degree of mitochondrial fission deficiency, ranging from severe encephalopathy and death shortly after birth to initially normal development and then sudden onset of refractory status epilepticus with very poor neurologic outcome. We describe a case of a previously healthy 3-year-old boy with a mild delay in speech development until the acute onset of a refractory status epilepticus with subsequent epileptic encephalopathy and very poor neurologic outcome. The de novo missense mutation in DNM1L (c.1207C > T, p.R403C), which we identified in this case, seems to determine a unique clinical course, strikingly similar to four previously described patients in literature with the identical de novo heterozygous missense mutation in DNM1L.


Neurology ◽  
2003 ◽  
Vol 61 (3) ◽  
pp. 398-401 ◽  
Author(s):  
Mustafa Sahin ◽  
Caroline C. Menache ◽  
Gregory L. Holmes ◽  
James J. Riviello

2014 ◽  
Vol 125 ◽  
pp. S154-S155
Author(s):  
C. Lazo La Torre ◽  
M. Vicente Rasoamalala ◽  
E. Lainez Samper ◽  
R. Rossich Verdes ◽  
M. Veciana de las Heras ◽  
...  

2018 ◽  
Vol 47 ◽  
pp. 149-151 ◽  
Author(s):  
Lauren Koffman ◽  
Ho Yan Yiu ◽  
Salia Farrokh ◽  
John Lewin ◽  
Romergryko Geocadin ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-7
Author(s):  
Christopher R. Newey ◽  
Naresh Mullaguri ◽  
Stephen Hantus ◽  
Vineet Punia ◽  
Pravin George

Introduction. Acute symptomatic seizures are frequent in the critically ill patient and can be difficult to treat. The novel anticonvulsant perampanel may be effective in the treatment of status epilepticus considering its mechanism of action of being an AMPA antagonist. We present four cases of super refractory status epilepticus treated with high dose perampanel. Method. Case report. Cases. Four patients were treated with perampanel for their refractory status epilepticus. One patient had new onset refractory status epilepticus of unknown etiology. Three other patients had status epilepticus as a result of their cardiac arrest. Two of the cardiac arrest patients had myoclonus. In all patients, the additional of perampanel resulted in a reduction of seizure burden without affecting hemodynamics or hepatic or renal function. Conclusion. Perampanel may be effective in the treatment of super-refractory status epilepticus of varying etiologies. A larger, prospective study is needed to further assess this therapy.


Epilepsia ◽  
2015 ◽  
Vol 56 (4) ◽  
pp. e44-e48 ◽  
Author(s):  
Maysaa M. Basha ◽  
Abdulradha Alqallaf ◽  
Aashit K. Shah

Sign in / Sign up

Export Citation Format

Share Document